Loading
A patient-derived xenograft is a patient's tumour grown in a mouse, used to test drugs before they reach people.
A patient-derived xenograft is made by implanting fresh tumour tissue into immunodeficient mice and passaging it, giving an in vivo model that retains histology and genomics better than cell lines. PDX models are used for ADC and combination testing (Champions Oncology, Crown Bioscience, Jackson Laboratory), where bystander and stromal effects can be observed in a way that culture cannot show. Humanised-mouse PDX, in which a human immune system is reconstituted, enables immunotherapy testing. The trade-offs are that mouse stroma progressively replaces human stroma, models take months to establish, and the cost limits how many patients can be modelled. The simple version is that a PDX lets researchers try a treatment on a copy of a real patient's tumour in a mouse before trying it in people.
Fresh tumour implanted into immunodeficient mice and passaged.
Query for this technology: (TITLE:"patient-derived xenograft" OR ABSTRACT:"patient-derived xenograft" OR TITLE:"PDX model" OR ABSTRACT:"PDX model"). Results are unfiltered search hits about Patient-derived xenografts, not a curated reading list.
Shares Tumour-on-a-chip, An independent replication institute that re-tests key preclinical cancer findings before trials, Genetically engineered mouse models, Barcode patient-derived tumours to watch which clones win under each drug.
Shares Build laboratory models of the organs cancer spreads to, Humanised mice with an immune system matched to the tumour donor, Zebrafish avatars for a drug answer within a week, Make bespoke mouse cancer models in weeks with in vivo gene editing.
Shares Certis Oncology Solutions, Zebrafish avatars for a drug answer within a week, Organoid, Biobanking and tissue procurement.
Shares Barcode patient-derived tumours to watch which clones win under each drug, Make bespoke mouse cancer models in weeks with in vivo gene editing, The Jackson Laboratory Cancer Center, A pre-competitive consortium to validate or kill academic targets before licensing.
Shares A pre-competitive consortium to validate or kill academic targets before licensing, Make in vivo metastasis screens a required step in drug discovery, An open model bank for the rare tumours nobody has models for, Preclinical results do not reproduce.
Shares Model organism, Organoid, In vitro and in vivo, Preclinical.
Shares An independent replication institute that re-tests key preclinical cancer findings before trials, Multi-centre randomised animal trials before committing to a human trial, A funded organoid and PDX panel as the go/no-go gate before IND-enabling money, A pre-competitive consortium to validate or kill academic targets before licensing.
Shares Run the mouse or organoid trial at the same time as the human trial, Organoid-guided therapy at scale, Test drugs on the patient's own cancer cells when there is no trial to join, Lab models that fail to predict what happens in patients.